Researchers in Prof. Matthew Scott's laboratory have discovered that small-molecule inhibitors of casein kinase II (CK2) could be used as a targeted therapy for pediatric medulloblastoma or other Shh/hedgehog-related tumors.
Stanford researchers in the Brongersma Lab have developed an integrated dynamic flat-optics system as part of a comprehensive optofluidic platform, enabling unprecedented compact configurations.
Colorectal cancer affects 1.4 million new patients annually, with existing treatments often ineffective. A key factor in treatment resistance is high aldehyde dehydrogenase activity, which undermines several chemotherapies.
A team of Stanford engineers has identified first-in-class epidermal growth factor (EGF) mutants with enhanced activity. These mutants can stimulate increased EGF receptor activation at 10-fold lower concentrations than wild-type EGF.
Stanford researchers at the Zhao Lab have developed a wireless, magnetically actuated amphibious origami millirobot that can locomote in narrow spaces and morph their shapes. The researchers have demonstrated that this millirobot can travel on surfaces and through liquid.
Stanford scientists have developed a neuroprotective, adeno-associated virus (AAV) gene therapy vector that expresses a mutant form of HDAC4 or a fragment of HDAC4 with novel applications to retinal and neurologic diseases, including glaucoma and other retinal ganglion cell di
Researchers at Stanford have demonstrated the first method of its kind for treating cystic fibrosis (CF) using regenerated airway stem cells embedded on a biocompatible scaffold.
Stanford scientists have developed novel, inhibitory chimeric antigen receptor T cells (iCARs) based on immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing signaling domains that can inhibit standard activating CAR (aCARs) activity (see figure* below).
Stanford researchers developed a framework called 'Hummingbird' that predicts the cheapest, fastest and most efficient configurations to execute genomics pipelines on the cloud.
Researchers in the Roncarolo have discovered transcription factors that enable the tracking and differentiation of type 1 T regulatory (Tr1) cells for the treatment of autoimmune conditions.
Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Researchers at Stanford have developed a potentially curative treatment strategy for alpha-thalassemia, one of the most common autosomal recessive disorders in the world involving the genes HBA1 and/or HBA2.